HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

AbstractBACKGROUND & AIMS:
Cholangiocarcinoma, the second most common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma. We performed an integrative genomic analysis of ICC samples from a large series of patients.
METHODS:
We performed a gene expression profile, high-density single-nucleotide polymorphism array, and mutation analyses using formalin-fixed ICC samples from 149 patients. Associations with clinicopathologic traits and patient outcomes were examined for 119 cases. Class discovery was based on a non-negative matrix factorization algorithm and significant copy number variations were identified by Genomic Identification of Significant Targets in Cancer (GISTIC) analysis. Gene set enrichment analysis was used to identify signaling pathways activated in specific molecular classes of tumors, and to analyze their genomic overlap with hepatocellular carcinoma (HCC).
RESULTS:
We identified 2 main biological classes of ICC. The inflammation class (38% of ICCs) is characterized by activation of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation. The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC. Copy number variation-based clustering was able to refine these molecular groups further. We identified high-level amplifications in 5 regions, including 1p13 (9%) and 11q13.2 (4%), and several focal deletions, such as 9p21.3 (18%) and 14q22.1 (12% in coding regions for the SAV1 tumor suppressor). In a complementary approach, we identified a gene expression signature that was associated with reduced survival times of patients with ICC; this signature was enriched in the proliferation class (P < .001).
CONCLUSIONS:
We used an integrative genomic analysis to identify 2 classes of ICC. The proliferation class has specific copy number alterations, activation of oncogenic pathways, and is associated with worse outcome. Different classes of ICC, based on molecular features, therefore might require different treatment approaches.
AuthorsDaniela Sia, Yujin Hoshida, Augusto Villanueva, Sasan Roayaie, Joana Ferrer, Barbara Tabak, Judit Peix, Manel Sole, Victoria Tovar, Clara Alsinet, Helena Cornella, Brandy Klotzle, Jian-Bing Fan, Christian Cotsoglou, Swan N Thung, Josep Fuster, Samuel Waxman, Juan Carlos Garcia-Valdecasas, Jordi Bruix, Myron E Schwartz, Rameen Beroukhim, Vincenzo Mazzaferro, Josep M Llovet
JournalGastroenterology (Gastroenterology) Vol. 144 Issue 4 Pg. 829-40 (Apr 2013) ISSN: 1528-0012 [Electronic] United States
PMID23295441 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Topics
  • Aged
  • Bile Duct Neoplasms
  • Bile Ducts, Intrahepatic
  • Biopsy, Needle
  • Cholangiocarcinoma (classification, genetics, mortality, pathology)
  • DNA Copy Number Variations
  • DNA Mutational Analysis
  • Databases, Factual
  • Disease Progression
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genetic Predisposition to Disease (epidemiology)
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization
  • Kaplan-Meier Estimate
  • Liver Neoplasms (classification, genetics, mortality, pathology)
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: